In NSCLC, DSCAM-AS1 participates in a competitive endogenous mechanism: DSCAM-AS1 indirectly upregulates FSTL3 expression by acting as a competing endogenous RNA against miR-122-5p, thereby accelerating the development and progression of NSCLC (Figure 2G) (Gao et al., 2020). The gene discussed is FSTL3; the disease is non-small cell lung carcinoma.